Phase 1 trial of valemetostat and darolutamide in mCRPC
DS3201-343
Phase 1 other active
Quick answer
Phase 1 trial of valemetostat and darolutamide in mCRPC for Metastatic Castration Resistant Prostate Cancer (mCRPC) is a Phase 1 program (other) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo Europe GmbH
- Indication
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Phase
- Phase 1
- Modality
- other
- Status
- active